Lupin launches generic ophthalmic medication in US
Lupin, an Indian drug firm, has introduced a generic eye medication in the US. This medication, Loteprednol Etabonate Ophthalmic Suspension, treats eye inflammation and pain. It is a bioequivalent to Bausch & Lomb's Lotemax. The drug addresses pos...
The company has launched Loteprednol Etabonate Ophthalmic Suspension, a bioequivalent to Bausch & Lomb Inc's Lotemax Ophthalmic Suspension, in the US market, the Mumbai-based drug maker said in a statement.
Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, is a steroid medication used to treat inflammation and pain in the eye, particularly after surgery or due to conditions like allergic conjunctivitis.
It is also indicated for the treatment of post-operative inflammation following ocular surgery.
As per the IQVIA MAT May 2025 data, Loteprednol Etabonate Ophthalmic Suspension had estimated annual sales of USD 55 million in the US.
Lupin shares on Wednesday ended 1.04 per cent down at Rs 1,931.10 apiece on BSE.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.